FucT is a class of biosynthetic enzymes involved in the synthesis of fucosylated oligosaccharides. It catalyzes the transfer of L-fucose from the guanosine-diphosphate-L-fucose to a variety of sugar-acceptor substrates, including oligosaccharides, glycoproteins, and glycolipids. Fucosylation of fucose is often the final step in the biosynthesis of oligosaccharides and glycoconjugates. L-fucose-containing glycoconjugates are essential for a wide range of physiological and pathological activities, such as inflammation, bacterial and viral infections, tumor metastasis, genetic disorders, etc. FucTs are highly expressed in liver cancer, lung cancer, epithelial ovarian cancer, colonic carcinoma, etc. They may be involved in metastatic processes, as well as play an important role in the repair of the airway mucosa, and are involved in embryo implantation.
At CD BioGlyco, our FucT engineering service is designed to address this challenge by providing tailored solutions for the rational design and optimization of FUT enzymes. Leveraging our deep expertise in glycoengineering, we enable our clients to precisely control the fucosylation profile of their target molecules, accelerating the development of next-generation biologics with enhanced therapeutic properties.
Our FucT engineering services rest on a robust framework of advanced genetic engineering technologies, enabling precise control over cellular fucosylation pathways. The core techniques here involve gene knockout, overexpression, silencing, and knockdown. Through these sophisticated genetic tools, we develop stable engineered cell lines that generate glycoproteins with consistent, optimized fucosylation patterns.
CD BioGlyco optimizes the experimental conditions in the course of long-term cell and mouse research. We provide a variety of cell lines and animal model products for different customers' research needs. Our FUT gene editing service includes the following parts.
In plants, the functions related to O-fucosylation are less studied. Its catalytic key enzyme, namely O-fucosyltransferase (POFUT), lacks systematic research, and O-fucosylation-modifying proteins are not identified. We verify the function of POFUT in plants by overexpression, silencing, Knockdown, and other technologies for gene modification.
Fig.1 One-stop FUT gene editing process. (CD BioGlyco)
Paper Title: FUT1-mediated terminal fucosylation acts as a new target to attenuate renal fibrosis
Technology: Gene Overexpression
Journal: Molecular Medicine
IF: 5.7
Published: 2023
Results: The results of overexpression of FUT1 in human kidney proximal tubular epithelial cells (HK-2) showed that FUT1 overexpression increased terminal fucoidan glycosylation in HK-2 cells. TGF-β1 stimulation induced HK-2 cells to form a spindle-like shape and detach from neighboring cells. Overexpression of FUT1 is found to further promote TGF-β1-induced aberrant cell morphology. Overexpression of FUT1 combined with TGF-β1 treatment significantly increases the epithelial-mesenchymal transition (EMT) process in HK-2 cells. FUT1-mediated terminal fucosylation could promote renal fibrosis through EMT.
Fig.2 FUT1 promotes renal fibrosis in HK-2 cells. (Luo, et al., 2023)
CD BioGlyco has rich experience in cell biology, molecular biology, in vitro biology, and other fields. We provide a complete set of gene editing services. In addition to FucT, we also provide Sialyltransferase Engineering Service and Glucuronyltransferase Engineering Service. If you want to know more about them, please feel free to contact us.
Our team synthesizes complex fucosylated glycans for use as substrates or standards.
Our antibody glycoengineering service address a wide range of modifications beyond fucosylation.
Reference
About Us
CD BioGlyco is a leading biotechnology company specializing in glycobiology. We deliver high-quality products and services to support cutting-edge research worldwide.